TriSalus already has two HCPCS C codes for complex embolization procedures using pressure-generating catheters in hospital outpatient departments and ambulatory surgery centers. The company sees liver embolization as an initial opportunity in the setting, along with uterine, prostate and genicular artery embolization procedures. Beyond liver procedures, TriSalus is advancing studies in uterine artery embolization, thyroid artery embolization and genicular artery embolization. The uterine artery embolization study remains on track toward a 50-patient target, while the company’s PROTECT thyroid registry has reached the enrollment cutoff for an interim analysis. About TriSalus Life Sciences (NASDAQ:TLSI)TriSalus Life Sciences, Inc is a clinical-stage biotechnology company focused on the development and commercialization of non-invasive drug–device combination therapies for oncology applications.